Cargando…
The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts
INTRODUCTION: Cardiometabolic syndrome (CMS), as a bunch of metabolic disorders mainly characterized by type 2 diabetes mellitus (T2DM), hypertension, atherosclerosis, central adiposity, and abdominal obesity triggering androgen deficiency, is one of the most critical threats to men. Although many s...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261691/ https://www.ncbi.nlm.nih.gov/pubmed/32201216 http://dx.doi.org/10.1016/j.esxm.2020.02.006 |
_version_ | 1783540542586486784 |
---|---|
author | Kirlangic, Omer Faruk Yilmaz-Oral, Didem Kaya-Sezginer, Ecem Toktanis, Gamze Tezgelen, Aybuke Suveyda Sen, Ekrem Khanam, Armagan Oztekin, Cetin Volkan Gur, Serap |
author_facet | Kirlangic, Omer Faruk Yilmaz-Oral, Didem Kaya-Sezginer, Ecem Toktanis, Gamze Tezgelen, Aybuke Suveyda Sen, Ekrem Khanam, Armagan Oztekin, Cetin Volkan Gur, Serap |
author_sort | Kirlangic, Omer Faruk |
collection | PubMed |
description | INTRODUCTION: Cardiometabolic syndrome (CMS), as a bunch of metabolic disorders mainly characterized by type 2 diabetes mellitus (T2DM), hypertension, atherosclerosis, central adiposity, and abdominal obesity triggering androgen deficiency, is one of the most critical threats to men. Although many significant preclinical and clinical findings explain CMS, new approaches toward common pathophysiological mechanisms and reasonable therapeutic targets are lacking. AIM: To gain a further understanding of the role of androgen levels in various facets of CMS such as the constellation of cardiometabolic risk factors including central adiposity, dyslipidemia, insulin resistance, diabetes, and arterial hypertension and to define future directions for development of effective therapeutic modalities. METHODS: Clinical and experimental data were searched through scientific literature databases (PubMed) from 2009 to October 2019. MAIN OUTCOME MEASURE: Evidence from basic and clinical research was gathered with regard to the causal impact and therapeutic roles of androgens on CMS. RESULTS: There are important mechanisms implicated in androgen levels and the risk of CMS. Low testosterone levels have many signs and symptoms on cardiometabolic and glycometabolic risks as well as abdominal obesity in men. CLINICAL IMPLICATIONS: The implications of the findings can shed light on future improvements in androgen levels and add potentially predictive risk for CMS, as well as T2DM, abdominal obesity to guide clinical management in the early stage. STRENGTHS & LIMITATIONS: This comprehensive review refers to the association between androgens and cardiovascular health. A limitation of this study is the lack of large, prospective population-based studies that analyze the effects of testosterone treatment on CMS or mortality. CONCLUSION: Low testosterone levels have several common features with metabolic syndrome. Thus, testosterone may have preventive role in the progress of metabolic syndrome and subsequent T2DM, abdominal obesity, and cardiovascular disease and likely affect aging men's health mainly through endocrine and vascular mechanisms. Further studies are necessary to evaluate the therapeutic interventions directed at preventing CMS in men. Kirlangic OF, Yilmaz-Oral D, Kaya-Sezginer E, et al. The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts. Sex Med 2020;8:132–155. |
format | Online Article Text |
id | pubmed-7261691 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-72616912020-06-01 The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts Kirlangic, Omer Faruk Yilmaz-Oral, Didem Kaya-Sezginer, Ecem Toktanis, Gamze Tezgelen, Aybuke Suveyda Sen, Ekrem Khanam, Armagan Oztekin, Cetin Volkan Gur, Serap Sex Med Review INTRODUCTION: Cardiometabolic syndrome (CMS), as a bunch of metabolic disorders mainly characterized by type 2 diabetes mellitus (T2DM), hypertension, atherosclerosis, central adiposity, and abdominal obesity triggering androgen deficiency, is one of the most critical threats to men. Although many significant preclinical and clinical findings explain CMS, new approaches toward common pathophysiological mechanisms and reasonable therapeutic targets are lacking. AIM: To gain a further understanding of the role of androgen levels in various facets of CMS such as the constellation of cardiometabolic risk factors including central adiposity, dyslipidemia, insulin resistance, diabetes, and arterial hypertension and to define future directions for development of effective therapeutic modalities. METHODS: Clinical and experimental data were searched through scientific literature databases (PubMed) from 2009 to October 2019. MAIN OUTCOME MEASURE: Evidence from basic and clinical research was gathered with regard to the causal impact and therapeutic roles of androgens on CMS. RESULTS: There are important mechanisms implicated in androgen levels and the risk of CMS. Low testosterone levels have many signs and symptoms on cardiometabolic and glycometabolic risks as well as abdominal obesity in men. CLINICAL IMPLICATIONS: The implications of the findings can shed light on future improvements in androgen levels and add potentially predictive risk for CMS, as well as T2DM, abdominal obesity to guide clinical management in the early stage. STRENGTHS & LIMITATIONS: This comprehensive review refers to the association between androgens and cardiovascular health. A limitation of this study is the lack of large, prospective population-based studies that analyze the effects of testosterone treatment on CMS or mortality. CONCLUSION: Low testosterone levels have several common features with metabolic syndrome. Thus, testosterone may have preventive role in the progress of metabolic syndrome and subsequent T2DM, abdominal obesity, and cardiovascular disease and likely affect aging men's health mainly through endocrine and vascular mechanisms. Further studies are necessary to evaluate the therapeutic interventions directed at preventing CMS in men. Kirlangic OF, Yilmaz-Oral D, Kaya-Sezginer E, et al. The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts. Sex Med 2020;8:132–155. Elsevier 2020-03-20 /pmc/articles/PMC7261691/ /pubmed/32201216 http://dx.doi.org/10.1016/j.esxm.2020.02.006 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Review Kirlangic, Omer Faruk Yilmaz-Oral, Didem Kaya-Sezginer, Ecem Toktanis, Gamze Tezgelen, Aybuke Suveyda Sen, Ekrem Khanam, Armagan Oztekin, Cetin Volkan Gur, Serap The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts |
title | The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts |
title_full | The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts |
title_fullStr | The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts |
title_full_unstemmed | The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts |
title_short | The Effects of Androgens on Cardiometabolic Syndrome: Current Therapeutic Concepts |
title_sort | effects of androgens on cardiometabolic syndrome: current therapeutic concepts |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261691/ https://www.ncbi.nlm.nih.gov/pubmed/32201216 http://dx.doi.org/10.1016/j.esxm.2020.02.006 |
work_keys_str_mv | AT kirlangicomerfaruk theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT yilmazoraldidem theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT kayasezginerecem theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT toktanisgamze theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT tezgelenaybukesuveyda theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT senekrem theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT khanamarmagan theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT oztekincetinvolkan theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT gurserap theeffectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT kirlangicomerfaruk effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT yilmazoraldidem effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT kayasezginerecem effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT toktanisgamze effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT tezgelenaybukesuveyda effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT senekrem effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT khanamarmagan effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT oztekincetinvolkan effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts AT gurserap effectsofandrogensoncardiometabolicsyndromecurrenttherapeuticconcepts |